he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-05-05帕金森氏病是什么病 这样于今帕金森病
- 2022-04-272013年国际抗癫痫执行委员会抗癫痫药使用指南
- 2022-04-05综述:癫痫持续状态诊治最新进展
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 控制癫痫患者再次抽搐,不包括可选药物?
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫治愈费用
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 综述:癫痫持续状态诊治最新进展
- 预测癫痫患者再入院风险
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 北京癫痫手术费用
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫患者手术评估新型工具
- 心率多少正常 如何保持正常心率不变
- NeuroImage:纤维球成像可用于癫痫的进展
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 油炸刀鱼 酥脆的美味食物
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- FDA警告怀孕期间使用丙戊酸钠药物
- 不注意这些问题,吃多少药都没用!
- 第一批国家级 癫痫中心单位获得认证并授权
- 抗癫痫药物预防新发癫痫:任重而道远
- 心理百科:春节期间小心疾病
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 癫痫治疗障碍仍难以克服
- 不同年龄段癫痫的病因是什么?
- FDA批准Aptiom用于治疗患者癫痫发作
- 儿童癫痫的早期症状 癫痫的原因
- 怎样识别癫痫病的更早征兆
- 西兰花的做法大全 煮成西兰花
- 现代小儿癫痫病有什么症状
- 癫痫病有什么办法治疗法 针对病因做治疗法
- 癫痫的治疗 治疗癫痫的偏方全本
- 第三届儿科脑瘤及相关疾病新进展论坛
- 孙子重病,爷爷握千万房产却不帮对于孝顺这事,也许我们都捏了
- 引起癫痫病发作的考量有哪些
- PM2.5危害极大 对付室内PM2.5研究员有妙招
- 最佳癫痫病病人方法症状是什么
- 太原癫痫病医院:患者用药指导7步曲,简单又好记!
- 怎么用科学的方法化疗癫痫病
- 儿童癫痫病的早期症状 诊断分类及表现
- 癫痫发作对卒中患者进行静脉溶栓的长期原属起效应